Democrats Gain Congress, Pressing Healthcare Pricing Shifts
Healthcare providers and drug makers should expect a push to restore ACA subsidies and expand Medicare pricing negotiation.
Updated on Nov. 4, 2026 in Healthcare
Live Poll
Do you think health coverage and drug costs in the US are getting better or worse?
Democrats won control of both the House and Senate in the 2026 US midterm elections, with projections of 54 Senate seats and 224 House seats. The shift is expected to bring pushback against the Trump administration's healthcare, drug pricing, and tariff changes, affecting healthcare businesses and drug makers from the 2027 session onward.
Why it matters
The Trump administration did not renew expired Affordable Care Act tax credits at the end of 2025 and has disenrolled hundreds of thousands of ACA enrollees, citing suspected fraud. A Democratic majority gives Congress a platform to challenge those moves, while Medicaid enrollment has already fallen sharply under budget cuts and tighter eligibility rules.
Democrats are projected to hold 54 Senate seats and 224 House seats after the November 4, 2026 midterms. The administration has struck Most Favoured Nation agreements with 26 large pharma groups, and hundreds of thousands of ACA enrollees have been disenrolled.
The players
Trump Administration
The executive branch led by President Donald Trump, which has set drug pricing policy through Most Favoured Nation agreements and tariff actions affecting importers.
Department of Health and Human Services
The federal agency that administers Medicare, Medicaid, and the Affordable Care Act, and oversees rulemaking that shapes healthcare providers and insurers.
Robert F. Kennedy Jr.
The Secretary of Health and Human Services, whose agency's activities Congress may investigate under a Democratic majority.
The details
Enhancing ACA subsidies and reversing Medicaid spending cuts would require a two-thirds majority in Congress, a threshold a narrow Democratic majority may not reach on its own. Congress could also use subpoena power through committee chairs to investigate activities at the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. Democrats are also expected to push for greater use of Medicare pricing negotiation, a mechanism introduced under the Biden administration's Inflation Reduction Act.
Timeline
End of 2025: Affordable Care Act tax credits expired and were not renewed by the administration.
November 4, 2026: US midterm elections gave Democrats control of the House and Senate.
Market Landscape
The Inflation Reduction Act's Medicare drug-price negotiation provisions, enacted under the Biden administration, set the framework that a Democratic Congress may now expand. Meanwhile, the Trump administration's Most Favoured Nation agreements with 26 large pharma groups represent a separate pricing approach that the new majority will have to weigh.
Healthcare operators should track whether a Democratic Congress moves to restore ACA subsidies and reverse Medicaid cuts, since those changes would alter payer mix and patient volume. Drug makers with Most Favoured Nation agreements or TrumpRx sales should monitor any expansion of Medicare pricing negotiation. Consult qualified counsel before adjusting contracts or pricing commitments.
The takeaway
Expect healthcare policy to become a contested area in the next Congress, with coverage and drug pricing at the center. Operators should calendar the new session's first committee hearings and watch any moves on Medicare pricing negotiation as a signal of future reimbursement changes.
What happens next
The new Congress is expected to take up Medicaid spending cuts, ACA subsidies, and Medicare pricing negotiation once it convenes in early 2027.
Further reading
For background on the policy fights ahead, see the Healthcare coverage on how federal pricing and coverage rules affect providers and drug makers.
Live Poll
Do you think health coverage and drug costs in the US are getting better or worse?
